Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy

BACKGROUND: Long-acting muscarinic antagonist/long-acting β(2)-agonist (LAMA/LABA) provide greater improvements in lung function and symptoms than inhaled corticosteroid (ICS)/LABA in patients with chronic obstructive pulmonary disease (COPD). This study evaluated symptom burden and Global Initiativ...

Descripción completa

Detalles Bibliográficos
Autores principales: Moretz, Chad, Hahn, Beth, White, John, Goolsby Hunter, Alyssa, Essoi, Breanna, Elliott, Caitlin, Ray, Riju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605915/
https://www.ncbi.nlm.nih.gov/pubmed/33149569
http://dx.doi.org/10.2147/COPD.S265037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605915/
https://www.ncbi.nlm.nih.gov/pubmed/33149569
http://dx.doi.org/10.2147/COPD.S265037

Ejemplares similares